Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David V Glidden

Showing results (21-30 of 266) with videos related to

Pageof 27
Sort By:
Clinical Trials (London, England)|October 23, 2025
Sample size estimation for the averted events ratioDavid T Dunn, Oliver T Stirrup, David V Glidden
Arthritis and Rheumatism|September 5, 2002
Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndromeEmily von Scheven, David V Glidden, Melissa E Elder
Journal of Vascular and Interventional Radiology : JVIR|March 5, 2002
Research publications in vascular and interventional radiology: research topics, study designs, and statistical methodsWilmer Huang, Jeanne M LaBerge, Ying Lu, et al.
BMC Medical Research Methodology|January 13, 2016
Crude incidence in two-phase designs in the presence of competing risksPaola Rebora, Laura Antolini, David V Glidden, et al.
JAMA Network Open|March 26, 2021
Mental Health and Psychosocial Risk and Protective Factors Among Black and Latinx Transgender Youth Compared With PeersStanley Ray Vance, Cherrie B Boyer, David V Glidden, et al.
Statistical Communications in Infectious Diseases|July 26, 2022
Sample size calculation for active-arm trial with counterfactual incidence based on recency assayFei Gao, David V Glidden, James P Hughes, et al.
Clinical Trials (London, England)|October 25, 2023
Estimating counterfactual placebo HIV incidence in HIV prevention trials without placebo arms based on markers of HIV exposureYifan Zhu, Fei Gao, David V Glidden, et al.
BMC Medical Research Methodology|June 26, 2023
Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted eventsDavid T Dunn, Oliver T Stirrup, Sheena McCormack, et al.
The Lancet. HIV|April 30, 2016
PrEP adherence among trans women in Brazil-access needed for this key population - Authors' replyJae Sevelius, Madeline B Deutsch, David V Glidden, et al.
The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.
Pageof 27

Showing results (21-30 of 266) with videos related to

Sort By:
Pageof 27
Clinical Trials (London, England)|October 23, 2025
Sample size estimation for the averted events ratioDavid T Dunn, Oliver T Stirrup, David V Glidden
Arthritis and Rheumatism|September 5, 2002
Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndromeEmily von Scheven, David V Glidden, Melissa E Elder
Journal of Vascular and Interventional Radiology : JVIR|March 5, 2002
Research publications in vascular and interventional radiology: research topics, study designs, and statistical methodsWilmer Huang, Jeanne M LaBerge, Ying Lu, et al.
BMC Medical Research Methodology|January 13, 2016
Crude incidence in two-phase designs in the presence of competing risksPaola Rebora, Laura Antolini, David V Glidden, et al.
JAMA Network Open|March 26, 2021
Mental Health and Psychosocial Risk and Protective Factors Among Black and Latinx Transgender Youth Compared With PeersStanley Ray Vance, Cherrie B Boyer, David V Glidden, et al.
Statistical Communications in Infectious Diseases|July 26, 2022
Sample size calculation for active-arm trial with counterfactual incidence based on recency assayFei Gao, David V Glidden, James P Hughes, et al.
Clinical Trials (London, England)|October 25, 2023
Estimating counterfactual placebo HIV incidence in HIV prevention trials without placebo arms based on markers of HIV exposureYifan Zhu, Fei Gao, David V Glidden, et al.
BMC Medical Research Methodology|June 26, 2023
Interpretation of active-control randomised trials: the case for a new analytical perspective involving averted eventsDavid T Dunn, Oliver T Stirrup, Sheena McCormack, et al.
The Lancet. HIV|April 30, 2016
PrEP adherence among trans women in Brazil-access needed for this key population - Authors' replyJae Sevelius, Madeline B Deutsch, David V Glidden, et al.
The Lancet. HIV|June 13, 2018
The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agentsDavid T Dunn, David V Glidden, Oliver T Stirrup, et al.
Pageof 27